Resolution of Bisphosphonate-Associated Osteonecrosis of the Mandible: Possible Application for Intermittent Low-Dose Parathyroid Hormone [rhPTH(1-34)

Abstract

Activation of bone cell populations including osteoclasts, osteoblasts, and osteocytes occurs to varying degrees with normal bone remodeling and at different phases of wound healing in an extraction socket or as a result of an inflammatory process secondary to periodontal disease or apical bone necrosis secondary to pulpal necrosis. Therapeutics that use bisphosphonates for the management of bone diseases such as osteoporosis, metastatic cancer, multiple myeloma, and Paget’s disease affect the balance of osteoclast, osteoblast, and osteocyte populations. Consequently, the normal physiologic response of the mandibular or maxillary bone to insult or injury may be compromised in these patients. ErratumJournal of Oral and Maxillofacial SurgeryVol. 65Issue 5PreviewIn the March 2007 issue of the Journal of Oral and Maxillofacial Surgery (Volume 65, Number 3), in the article entitled, “Resolution of Bisphosphonate-Associated Osteonecrosis of the Mandible: Possible Application for Intermittent Low-Dose Parathyroid Hormone [rhPTH(1-34)]” (J Oral Maxillofac Surg 65:573-580, 2007) by Harper and Fung, there is a dosing error reported by the authors as follows: The dose of Fosamax and the duration of the dose schedule originally reported by the patient as “70 mg daily for 1 year” were inaccurate. Full-Text PDF